Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis

Hepatology

Volumn 49, Issue 6, 2009, Pages 1795-1797

  Glaser, Shannon S ^a   Alpini, Gianfranco ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24 NORURSODEOXYCHOLIC ACID; ANTICHOLELITHIASIS AGENT; APICAL SODIUM BILE ACID COTRANSPORTER 2; BINDING PROTEIN; DIGESTIVE TRACT AGENT; DINORURSODEOXYCHOLIC ACID; ILEAL BINDING PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

BILE DUCT DISEASE; CHOLEHEPATIC SHUNT; CHOLESTASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; ENTERITIS; HEPATOBILIARY PARAMETERS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION TEST; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

ANIMALS; BILE DUCTS; CHOLANGITIS, SCLEROSING; EPITHELIAL CELLS; HEPATOCYTES; HUMANS; URSODEOXYCHOLIC ACID;

EID: 68949136756     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22969     Document Type: Editorial

References (20)

1. Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 2007;27:214-226.
2. Lee YM, Kaplan MM. Primary sclerosing cholangitis.NEngl J Med 1995; 332:924-933.
3. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol 2008;24:377-383.
4. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: Summary of a workshop. HEPATOLOGY 2006;44:746-764.
5. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006;26:42-51.
6. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005;11:62-72.
7. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
8. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
9. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-1562.
10. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
11. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
12. -/- mice. HEPATOLOGY 2009; doi:10.1002/hep.22891.
13. Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. HEPATOLOGY 2005;42:1391-1398.
14. Strazzabosco M, Sakisaka S, Hayakawa T, Boyer JL. Effect of UDCA on intracellular and biliary pH in isolated rat hepatocyte couplets and perfused livers. Am J Physiol 1991;260:G58-G69.
15. Alpini G, Glaser S, Baiocchi L, Francis H, Xia X, Lesage G. Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats. HEPATOLOGY 2005;41:1037-1045.
16. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-481.
17. Crawford AR, Smith AJ, Hatch VC, Oude Elferink RP, Borst P, Crawford JM. Hepatic secretion of phospholipid vesicles in the mouse critically depends on mdr2 or MDR3 P-glycoprotein expression. Visualization by electron microscopy. J Clin Invest 1997;100:2562-2567.
18. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004;127:261-274.
19. Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008;158:542-548.
20. Fickert P, Moustafa T, Trauner M. Primary sclerosing cholangitis-the arteriosclerosis of the bile duct? Lipids Health Dis 2007;6:3.